Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile for acute gout flare
NL-OMON59024Phase 3Recruiting
- Sponsor
- Olatec Therapeutics LLC
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gout and acute gout flare comparing dapansutrile with placebo (2 arms). Primary endpoint: Change from baseline in target joint pain intensity at 72 hours. Started Oct 2024; status: recruiting.
02
Drugs
dapansutrile
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on NL-OMON59024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59024.